علاج جديد لمرض باركنسون معتمد من إدارة الغذاء والدواء الأمريكية
آخر تحديث 01 نوفمبر 2019
يمكنك الحصول على الأدوية الجديدة بشكل قانوني، حتى لو لم تتم الموافقة عليها في بلدك.
تعلّم كيفThis is a summary of an article on Endpoint News.
Japanese pharma group, Kyowa Hakko Kirin, won FDA approval for a Parkinson’s disease medicine, istradefylline, branded as Nourianz. The medicine is approved as an add-on to the first-line treatment levodopa/carbidopa.
Nourianz (istradefylline) is reported to play a role in controlling voluntary movement. The medicine won approval based on four 12-week placebo-controlled clinical studies with 1,143 participants. Patients showed a statistically significant decrease in 'off episodes' (the amount of time when the first-line medicines are not working well) from baseline compared to placebo.
Source
Natalie Grover. Decades in the making, Kyowa Hakko Kirin finally wins FDA approval for add-on Parkinson's therapy. Endpoint News. 28/08/2019.